Equities

Jin Medical International Ltd

ZJYL:NAQ

Jin Medical International Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.44
  • Today's Change-0.17 / -10.56%
  • Shares traded528.79k
  • 1 Year change+215.44%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Jin Medical International Ltd grew revenues 3.29% from 19.19m to 19.82m while net income improved 6.34% from 2.71m to 2.88m.
Gross margin34.73%
Net profit margin13.99%
Operating margin11.55%
Return on assets7.80%
Return on equity11.67%
Return on investment11.27%
More ▼

Cash flow in USDView more

In 2023, Jin Medical International Ltd increased its cash reserves by 44.59%, or 2.14m. Cash Flow from Financing totalled 6.91m or 34.86% of revenues. In addition the company generated 3.11m in cash from operations while cash used for investing totalled 7.73m.
Cash flow per share0.0196
Price/Cash flow per share82.70
Book value per share0.1676
Tangible book value per share0.1605
More ▼

Balance sheet in USDView more

Jin Medical International Ltd has a Debt to Total Capital ratio of 27.02%.
Current ratio2.58
Quick ratio2.27
Total debt/total equity0.3689
Total debt/total capital0.2702
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 17.20%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)21.92
EPS (TTM) vs
TTM 1 year ago
-16.49
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.